Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib (N) has proven more potent than L. However, the efficacy o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:NPJ Breast Cancer
Egile Nagusiak: Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8159999/
https://ncbi.nlm.nih.gov/pubmed/34045483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00274-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak